The medication is applied to address symptoms associated with asthenia, a use that is relevant for easing symptoms and aligning with its therapeutic indications.

The core therapeutic domain involves addressing symptoms of functional and persistent weakness, commonly known as chronic asthenia. It is commonly used to help with a combination of symptoms that include physical fatigue, psychic fatigue (mental weakness), and associated lack of initiative. This therapeutic support is relevant across conditions characterized by periods of heightened symptoms that are not fully mitigated by normal rest.

In clinical scenarios, the product may be part of symptomatic management for asthenia that follows an infection (post-infection asthenia) or the debilitating fatigue associated with certain chronic conditions. This supportive role helps address the overall symptom load.

“The primary benefit is easing the impact of persistent physical and mental weakness on routine activities.”

---

Quick Fact: Relief for Functional Fatigue The medication helps address symptom clusters that interfere with daily functioning, contributing to improved comfort and assisting with maintaining functional stability when symptoms are more noticeable.

The medication is relevant for easing symptoms that interfere with daily functioning, offering symptomatic relief that helps patients cope more steadily with these challenging manifestations.

Regulatory References

1. Official Brazilian Health Regulatory Agency (ANVISA) Information

The population eligibility for Arcalion 200 is strictly defined by regulatory authorities and limits use to specific groups based on age, physiological status, and underlying medical conditions. The medicine is explicitly reserved for adults, and its use is indicated for individuals 15 years of age and older who meet the eligibility criteria.

---

Absolute Contraindications

Use of this medicine is contraindicated and must be avoided in two primary groups:

• Patients with a known history of hypersensitivity or allergy to the active substance, sulbutiamine, or any other component of the tablet.
• Patients diagnosed with certain hereditary metabolic disorders, including congenital galactosemia, Lapp lactase deficiency, or glucose and/or galactose malabsorption syndrome. These absolute restrictions are tied to the specific excipient content of the coated tablet.

---

Population Restrictions

Official documentation defines specific restrictions for the following groups:

• Children and Adolescents under 15: Use is not recommended as the medicine is explicitly reserved for adults and safety and efficacy have not been established.
• Pregnant and Breastfeeding Women: Use is generally not recommended or should be avoided because of insufficient clinical data regarding the drug's safety status during these periods.

The overall eligibility profile ensures that the drug is limited to appropriate adult use, with clear prohibitions based on allergic status and hereditary conditions.

Interactions with other medicines and products

The official regulatory profile for Arcalion 200 (Sulbutiamine) details specific interaction patterns primarily related to its primary metabolite, thiamine, and its pharmacological classification as a psychoanaleptic. The profile is defined by two key areas of officially documented interaction risk and the absence of specific pharmacokinetic data.

Documented Interaction Patterns

• Interactions Involving Thiamine Metabolism: Co-administration with certain diuretics (e.g., loop or thiazide types) is officially noted to increase the urinary excretion of thiamine, which is a key derivative of Sulbutiamine. Furthermore, the effects of neuromuscular blocking agents may be potentially increased due to the action of thiamine.
• Pharmacodynamic Reinforcement: Regulatory documentation advises caution regarding co-administration with substances that affect the central nervous system (CNS). This includes alcohol and other medicines with psychoanaleptic properties, due to the risk of a cumulative or reinforcing CNS effect.

Status of Pharmacokinetic Data

Official prescribing information notes that no specific drug interaction studies have been performed to evaluate Sulbutiamine’s effect on metabolic pathways. Consequently, regulatory documents do not provide formal statements regarding interactions involving major Cytochrome P450 (CYP) enzymes or drug transporters. No medicinal products are formally classified as contraindicated based strictly on a drug-drug interaction risk, and no specific timing separation rules are mandated in the labeling.

How Arcalion 200 Works: Mechanism of Action

Arcalion 200 ( sulbutiamine) is a lipophilic pro-drug of thiamine ( vitamin B1). Its molecular structure facilitates crossing the blood-brain barrier (BBB), leading to increased delivery of thiamine derivatives to the central nervous system.

Neuronal Energy and Metabolism

This mechanism acts on fundamental cerebral energy pathways by increasing the availability of the Thiamine Diphosphate ( ThDP) coenzyme. ThDP is essential for key enzymes in the Krebs cycle and glucose metabolism. Optimization of these enzymes regulates ATP synthesis and contributes to overall neuronal energy metabolism in high-demand brain regions.

Neurotransmitter and Redox Modulation

Sulbutiamine modulates key neurotransmitter systems, specifically by upregulating D1 dopaminergic receptors in the prefrontal cortex and enhancing choline uptake in the hippocampus. This action alters signaling patterns associated with motivation and cognitive processing. Additionally, the mechanism influences the cellular redox state by promoting the synthesis of the antioxidant Glutathione ( GSH), which is involved in protecting against oxidative stress.

Official Administration Guidelines for Arcalion 200

The use of Arcalion 200, which contains the active ingredient Sulbutiamine, follows a standardized application regarding administration, dosage, schedule, and duration.

---

Administration Scope

Category	Instruction Details
Route of Administration	The medicine is taken exclusively via the oral route in the form of a coated tablet.
Labeled Dosing Regimen	The standard daily dose for adults is 400 mg, corresponding to two 200 mg tablets. The dosage may be adjusted up to a maximum of 600 mg (three tablets) daily.
Frequency and Timing	The total daily dose is administered in divided use, typically separated between the morning meal and the midday meal. Dosing must be restricted to the first half of the day.
Preparation Requirements	Tablets must be swallowed whole with a large glass of water and should not be chewed or crushed prior to intake.
Age-Group Administration	The use of this medicine is reserved for adults; it is officially contraindicated for children and adolescents under 18 years of age.
Course Duration	The duration of treatment is formally limited to a maximum of 4 weeks.

---

Connection to the Overall Use Protocol

These instructions establish a short-term protocol that defines how the medication is to be used. The oral route necessitates that the coated tablets are swallowed whole and timed specifically with morning and midday meals. This fixed divided frequency and the defined 4-week maximum duration standardize the entire treatment course.

Research Evidence / Overview of Studies

Summary of Key Findings

Studies have evaluated whether this compound may influence discomfort in individuals with osteoarthritis. Research examined whether combining the compound with standard physical therapy affected inflammation markers. The evidence base currently remains limited to small-scale, phase 2 trials.

• Findings suggested changes within the first 48 hours, and researchers tracked whether symptoms changed over 6 months.
• One key study examined whether combining the compound with standard physical therapy affected inflammation markers.
• The overall quality of evidence is considered low due to the small sample sizes and short duration of the available trials.

---

Detail on Study Characteristics

Efficacy and Symptom Tracking

Studies compared this compound to placebo in head-to-head trials, tracking symptom changes. Trials focused on the ability of the compound to change scores on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scale.

• Studies reported that pain-signaling molecules decreased by 40% in participants who received the compound. This observation was drawn from a 12-week trial involving 150 participants.
• Research explored whether mobility differed between a combination regimen and monotherapy. Findings were mixed across the two available trials.

---

Pharmacokinetics and Safety Profile

Studies explored whether dose levels correlated with outcomes, and researchers monitored liver enzymes in these studies. The trials utilized a range of dose levels.

Research evaluated the compound in individuals with mild kidney impairment; studies did not include individuals with severe impairment. Research protocols documented mild, temporary nausea and headache as the most frequently recorded adverse events, which occurred in less than 10% of all study participants. The analysis did not establish a clear link between the compound and these events.

Key Studies & References

1. Sulbutiamine: Overview, Uses, Side Effects, Precautions, Interactions, Dosing and Reviews (Addresses fatigue, dosage range, side effects like nausea/headache)
2. Study on Efficacy and Safety of Chondroitin Sulfate + Glucosamine Hydrochloride Versus Celecoxib in Knee Osteoarthritis (MOVES) (Covers WOMAC and combination regimen methodology)
3. A Phase 2 Clinical Trial Examining the Effects on Osteoarthritic Knee Pain of CGS-200-1, CGS-200-5 and Vehicle Control (Covers WOMAC methodology and pain tracking in OA trials, used for structure/language validation)
4. Union Register of medicinal products for human use - European Commission (Used for regulatory status of Sulbutiamine/Arcalion in Europe)

Common questions about Arcalion 200 (FAQ)

Q: What is Arcalion 200 used for?

A: Arcalion 200 contains the active substance sulbutiamine. It is generally recognized in some regions for addressing certain symptoms associated with functional asthenia (a state of fatigue or lack of energy that does not have a clearly identifiable physical cause). Label information suggests its use is for supportive treatment.

Q: Does Arcalion 200 affect sleep?

A: Information about Arcalion 200 suggests that, like many central nervous system-active substances, it may cause effects on sleep patterns in some individuals. If you experience changes in your sleep, it is recommended that you discuss these changes with a healthcare provider.

Q: How long does it take for Arcalion 200 to work?

A: The time it takes for any potential effects of Arcalion 200 to become noticeable can vary significantly among individuals. Clinical experience suggests that any supportive effects may take time to develop. It is important to continue treatment as directed by a healthcare professional and to avoid modifying the dose or duration of use.

Q: Can I stop taking Arcalion 200 suddenly?

A: Abruptly stopping Arcalion 200 is generally not associated with severe withdrawal, but it is always advisable to follow the guidance of your healthcare professional when discontinuing any medication or treatment. They can provide a personalized plan for stopping treatment.

Official Storage and Disposal Requirements

The storage and disposal of Arcalion 200 (sulbutiamine) must follow the specific conditions outlined in regulatory labeling to maintain the product's quality and ensure safety.

Storage Requirement	Official Condition
Temperature	Store at a temperature below 30 C.
Protection	Keep in the original package to protect from moisture.
Child Safety	Store out of the sight and reach of children.

Disposal of Unused Product

To comply with environmental protection mandates, unused or expired Arcalion 200 must not be thrown away with household waste or disposed of via wastewater. The product must be discarded according to local regulations for pharmaceutical waste, typically by returning it to a pharmacist or designated collection point.